Genprex (GNPX) Share-based Compensation (2016 - 2026)
Genprex (GNPX) posted quarterly Share-based Compensation of $300000.0 for Q1 2026, up 650.0% year-over-year from $40000.0 in Q1 2025, and up 182.59% quarter-over-quarter from -$363243.0 in Q4 2025.
Genprex (GNPX) Share-based Compensation (2016 - 2026) Analysis & Trends
Genprex's Share-based Compensation history runs 11 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 650.0% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $300000.0 (down 89.28% YoY), while the FY2025 annual figure was $320000.0, down 90.3% from the prior year.
- Share-based Compensation for Q1 2026 stood at $300000.0, up from -$363243.0 in the prior quarter.
- The five-year high for Share-based Compensation was $10.6 million in Q2 2022, with the low at -$363243.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $458917.0 (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 172668733.33% in 2024, then sank 237.06% in 2025.
- Genprex's Share-based Compensation stood at $1.3 million in 2022, then decreased by 20.31% to $1.0 million in 2023, then sank by 74.52% to $265034.0 in 2024, then tumbled by 237.06% to -$363243.0 in 2025, then jumped by 182.59% to $300000.0 in 2026.
- Business Quant data shows GNPX's Share-based Compensation at $300000.0 in Q1 2026, -$363243.0 in Q4 2025, and $19553.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 90,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | -363,243.00 |
| Dec 31, 2025 | -363,243.00 |
| Sep 30, 2025 | 19,553.00 |
| Sep 30, 2025 | 19,553.00 |
| Jun 30, 2025 | 458,917.00 |
| Jun 30, 2025 | 458,917.00 |
| Mar 31, 2025 | 40,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | 265,034.00 |
| Dec 31, 2024 | 265,034.00 |
| Sep 30, 2024 | 420,226.00 |
| Sep 30, 2024 | 420,226.00 |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |